Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005690 | 1.00 | HPGD (0.49) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL7002987 | 1.00 | HPGD (0.49) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL357043 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL178721 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL357042 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL31539240 | 0.88 | HPGD (0.48) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL27618621 | 0.88 | PREP (0.42) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL4175218 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL489128 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL489126 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026995-A | Dihydrotriazole aromatization precursor and application thereof in deacylating and arylating reaction of ketone | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | claimed |
| CN-115262212-B | Cotton fabric crease-resistant antibacterial finishing method based on organic silicon resin | 江苏自然风纺织品有限公司 | 2023-11-10 | — | — | CN | claimed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | claimed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4640279-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4356969-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| CN-119923395-A | N-heterocyclic GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof | 卡莫特医疗有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025051148-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京鞍石生物科技股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119585238-A | N- (pyrrolidin-3-yl or piperidin-4-yl) acetamide derivatives | 武田药品工业株式会社 | 2025-03-07 | — | — | CN | disclosed |
| CN-119320383-A | Nitrogen-containing heteroaryl compound, and preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003061598-A2 | SOLENOPSIN A, B AND ANALOGS AS NOVEL ANGIOGENESIS INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1138679-B1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEM RES (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
| US-6392059-B1 | THERAPY FOR ALZHEIMER'S DISEASE | SAGAMI CHEMICAL REASEARCH CENTER (JP) | 2002-05-21 | — | — | US | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
| EP-1138679-A1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2001-10-04 | — | — | EP | disclosed |
| CN-1076690-A | SULFONAMIDOCARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 1993-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | HPGD 764/4885GAA 36/4885HSD17B10 224/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | HPGD 1702/4885GAA 15/4885HSD17B10 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.